{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Number of participants who achieved a CR as Best Response.","groups":[{"description":"Participants who had failed standard of care including Venetoclax and Gilteritining based therapies.\n\nNMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.","id":"OG000","title":"Phase 2, Schedule B, Cohort 1:360+150 mg"},{"description":"Participants who have failed standard of care. NMS-03592088 was administered, on Cycle 1, at 360 mg/day (loading dose) for 5 consecutive days, followed by 150 mg/day (maintenance dose) for 23 consecutive days. The same maintenance dose (150 mg/day) was administered from Cycle 2 onwards.","id":"OG001","title":"Phase 2, Schedule B, Cohort 2: 360+150 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients evaluable for efficacy analysis (efficacy dataset):For Cohort 1 and Cohort 2, only the subset of participants with FLT3-ITD mutation and no D835 mutation based on the central test were included in this population.","reportingStatus":"POSTED","timeFrame":"From the date of first response up to end of study (approximately 1.5 years)","title":"For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)","type":"SECONDARY","unitOfMeasure":"Participants"}